Amino acid substitutions in the Candida albicans sterol 5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine the mechanisms responsible for fluconazole resistance in two Candida albicans isolates (CAAL2 and CAAL76) recovered from two hospitalized patients after fluconazole prophylaxis. METHODS: MICs of fluconazole and voriconazole were determined by the broth microdilution method (CLSI M27-A3), and by Etest(®) for amphotericin B. RNA expression levels of CDR1, MDR1 and ERG11 were determined by RT-PCR. Mutations in ERG11 and ERG3 were investigated by amplification and sequencing. Sterol membrane profiles were determined by gas chromatography-mass spectrometry (GC-MS). In vivo virulence was determined in a murine model of invasive candidiasis. RESULTS: Both isolates displayed azole cross-resistance and reduced susceptibility to amphotericin B, and are novel Δ(5,6)-desaturase (Erg3p) mutants. CAAL2 harbours a new amino acid substitution (L193R), whereas a 13 bp deletion leading to a truncated Erg3p (Δ366-378) was found in CAAL76. Both genetic alterations impaired Erg3p function as shown by GC-MS in these isolates (ergosterol content below 10%, and accumulation of ergosta-7,22-dienol above 40%). In vivo, in a murine model of invasive candidiasis, both CAAL2 and CAAL76 exhibited a significant trend toward reduced virulence, which seems to be linked to a reduced capacity for hyphal growth. CONCLUSIONS: These findings demonstrate the critical role of residue 193 in Erg3p function and azole resistance. We suggest that this attenuated in vivo virulence phenotype could be linked to lower potential for hyphal growth. Taken together, our findings highlight the fact that erg3 mutants must be considered in future studies aiming at investigating azole antifungal drug resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, the clinical isolates displayed cross-resistant to azoles and amphotericin B have been detected to be the ERG3 mutated strain.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [38]
In the citing paper
“And the direct evidence is that the upstream products of Erg3p, episterol and fecosterol, have accumulated about 10%.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [38]
In the citing paper
“These sterol composition data has provided a powerful evidence that the cross-resistance of clinical isolates depends on the mutation in ERG3 .”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [38]
In the citing paper
“In consistent with this, ergosta-7,22-dienol, which is the product of the alternative route bypassing the Erg3p accounts for about 50% of all the sterols.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [38]
In the citing paper
“ERG3 mutations leading to the depletion of ergosterol and the accumulation of less toxic sterols when ERG11 is inhibited have been implicated in cross-resistance between azoles and polyenes in S. cerevisiae and C. albicans40, 41, 42, 43 and between echinocandins and azoles in C. parapsilosis.44,45”
From Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata (2021) · cites this paper as [43]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398
Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., & Sanglard, D. (2006) · Genetics · doi:10.1534/genetics.105.054767 · Cited by 385
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305
Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1272 · Cited by 296
Sanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
Research works printed but not linked: 3
- Myoken, 2006, Haematologica, 91, 287
- 1999, 236, 43
- 1991, 102, 39
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“Only a handful of clinical C. albicans isolates have documented azole resistance due to ERG3 inactivation (Kelly et al., 1997; Nolte et al., 1997; Miyazaki et al., 1999; Chau et al., 2005; Martel et al., 2010; Morio et al., 2012).”
BackgroundAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“albicans and Candida dubliniensis [45, 62, 64, 65].”
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
“ERG3 mutants have been well studied in C. albicans and C. dubliniensis (Morio et al., 2012).”
BackgroundEmerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“Additionally, inactivation of the protein encoded by the ERG3 gene has also been found to confer azole resistance [59].”
BackgroundAlcazar-Fuoli, L., & Mellado, E. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00439 · Cited by 189
“Acquired resistance to AMB has been most extensively evaluated in yeasts and is associated with mutations in the ERG3 gene, which is linked to qualitative and quantitative alterations of membrane lipids and an absence of ergosterol (Kelly et al., 1997; Morio et al., 2012).”
BackgroundResistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Maubon, D., Garnaud, C., Calandra, T., Sanglard, D., & Cornet, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3404-7 · Cited by 162
Lv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Forastiero, A., Mesa-Arango, A. C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J. F., Grimalt, J. O., Gomez-Lopez, A., Cuesta, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-13 · Cited by 131
Candida albicans gains azole resistance by altering sphingolipid composition
Gao, J., Wang, H., Li, Z., Wong, A. H.-H., Wang, Y.-Z., Guo, Y., Lin, X., Zeng, G., Liu, H., Wang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06944-1 · Cited by 130
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“Quite a few mutations in ERG11 have been described, but only a few are directly connected to azole resistance [102,103].”
BackgroundCurrent status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
“Recently, combined mutations in both ERG11 and another enzyme of the ergosterol biosynthesis pathway (ERG3; encoding a C-5 sterol desaturase) seems to be emerging in C. albicans and C. tropicalis (Morio et al, 2012; Eddouzi et al, 2013; Forastiero et al, 2013; Jiang et al, 2013).”
BackgroundMolecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
Morschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Self-citationYadav, A., Singh, A., Wang, Y., Haren, M. H. V., Singh, A., de Groot, T., Meis, J. F., Xu, J., & Chowdhary, A. (2021) · Journal of Fungi · doi:10.3390/jof7020081 · Cited by 111
Ksiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
Elucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Nishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Spettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 78
“…of vaginal infection (Luna-Tapia et al. 2018) ERG3 mutations FLU, VOR, AMB C. albicans Reduced virulence in murine model of systemic infection (Morio et al. 2012) LOF mutation in ERG3 FLU C. albicans No change of virulence in murine model of systemic infection (Vale-Silva et al. 2012) MRR1…”
InfluentialFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“Some substitutions in the ERG3 gene (encoding a sterol-desaturase) may lead to loss of function of the enzyme, promote the accumulation of deleterious sterols, and allow the fungus to survive in the presence of fluconazole; however, these mechanisms are much less frequent (Morio et al., 2012).”
BackgroundCarolus, H., Sofras, D., Boccarella, G., Sephton-Clark, P., Biriukov, V., Cauldron, N. C., Lobo Romero, C., Vergauwen, R., Yazdani, S., Pierson, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01854-z · Cited by 72
Branco, J., Ola, M., Silva, R. M., Fonseca, E. S. S., Gomes, N. C., Martins-Cruz, C., Silva, A. P., Silva-Dias, A., Pina‐Vaz, C., Erraught, C., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.002 · Cited by 75
The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans
Li, X., Cai, Q., Mei, H., Zhou, X., Shen, Y., Li, D., & Liu, W. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv070 · Cited by 64
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63
“ERG3 loss of function mutations have 19 been documented in several fungal pathogens, all resulting in Amb resistance (26, 35-38).”
BackgroundErgosterol Biosynthesis and Regulation Impact the Antifungal Resistance and Virulence of Candida spp
Eliaš, D., Tóth Hervay, N., & Gbelská, Y. (2024) · Stresses · doi:10.3390/stresses4040041 · Cited by 63
“Deletion of genes involved in ergosterol biosynthesis (Table 2) affects the virulence of Candida spp. as has been shown in mouse models of candidiasis [27,43,116,159,160].”
Multidrug transporters of Candida species in clinical azole resistance
Prasad, R., Nair, R., & Banerjee, A. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103252 · Cited by 57
Garnaud, C., Botterel, F., Sertour, N., Bougnoux, M.-E., Dannaoui, E., Larrat, S., Hennequin, C., Guinea, J., Cornet, M., & Maubon, D. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv139 · Cited by 55
Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China
Liu, J.-Y., Shi, C., Wang, Y., Li, W.-J., Zhao, Y., & Xiang, M.-J. (2015) · Research in Microbiology · doi:10.1016/j.resmic.2015.02.009 · Cited by 54
Molecular bases of antifungal resistance in filamentous fungi
Sharma, C., & Chowdhary, A. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.018 · Cited by 55
Peraman, R., Sure, S. K., Dusthackeer, A., Chilamakuru, N. B., Reddy, Y. P., Chiranjeevi, P., Kutagulla, V. K., & Chinni, S. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-021-00196-5 · Cited by 59
“Therefore, if the fungus acquires azole resistance, it cannot produce the metabolite [32].”
BackgroundMorio, F., Pagniez, F., Besse, M., Gay‐Andrieu, F., Miegeville, M., & Pape, P. L. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.07.013 · Cited by 59
Self-citationNishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Yun, Y., Yin, D., Dawood, D. H., Liu, X., Chen, Y., & Ma, Z. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.04.010 · Cited by 54
Emerging Mechanisms of Drug Resistance in Candida albicans
Prasad, R., Nair, R., & Banerjee, A. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_6 · Cited by 45
Papp, C., Bohner, F., Kocsis, K., Varga, M., Szekeres, A., Bodai, L., Willis, J. R., Gabaldón, T., Tóth, R., Nosanchuk, J. D., et al. (2020) · mSphere · doi:10.1128/msphere.00821-20 · Cited by 42
“albicans the lack of sterol Δ5,6-desaturase activity leads to decreased virulence (33, 34).”
BackgroundCandida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance
Doorley, L. A., Rybak, J. M., Berkow, E. L., Zhang, Q. H., Morschhäuser, J., & Rogers, P. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00289-22 · Cited by 40
Sun, X., Wang, W., Wang, K., Yu, X., Liu, J., Zhou, F., Xie, B., & Li, S. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00127 · Cited by 37
“Many ERG3 mutants of S. cerevisiae or C. albicans with defects in C5-6 desaturase showed increased resistance to azoles (Watson et al., 1989; Martel et al., 2010a; Morio et al., 2012; Vale-Silva et al., 2012).”
BackgroundInfluentialDemuyser, L., Swinnen, E., Fiori, A., Herrera-Malaver, B., Verstrepen, K., & Van Dijck, P. (2017) · mBio · doi:10.1128/mbio.00201-17 · Cited by 33
Resistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
Alves, R. M. A., Kastora, S. L., Gomes-Gonçalves, A., Azevedo, N. F., Rodrigues, C. F., Silva, S. M., Demuyser, L., Dijck, P. V., Casal, M., Brown, A. J. P., et al. (2020) · npj Biofilms and Microbiomes · doi:10.1038/s41522-020-0114-5 · Cited by 34
“Sterol measurement Sterols were extracted according to the method described in Morio et al.80 with a few adaptations.”
MethodSynergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Musioł, R., Mrozek‐Wilczkiewicz, A., & Polański, J. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131218094848 · Cited by 35
Baker, K. M., Hoda, S., Saha, D., Gregor, J. B., Georgescu, L., Serratore, N. D., Zhang, Y., Cheng, L., Lanman, N. A., & Briggs, S. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02250-21 · Cited by 30
Luna-Tapia, A., Willems, H. M. E., Parker, J. E., Tournu, H., Barker, K. S., Nishimoto, A. T., Rogers, P. D., Kelly, S. L., Peters, B. M., & Palmer, G. E. (2018) · mBio · doi:10.1128/mbio.00225-18 · Cited by 29
Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species
Wadhwa, R., Pandey, P., Gupta, G., Aggarwal, T., Kumar, N., Mehta, M., Satija, S., Gulati, M., Madan, J., Dureja, H., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191026105308 · Cited by 30
Candida parapsilosis Sensu Stricto Antifungal Resistance Mechanisms and Associated Epidemiology
Franconi, I., Rizzato, C., Poma, N. V., Tavanti, A., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9080798 · Cited by 29
Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast
Ottilie, S., Goldgof, G. M., Calvet, C. M., Jennings, G. K., LaMonte, G., Schenken, J., Vigil, E., Kumar, P., McCall, L., Lopes, E. S. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b01037 · Cited by 26
Alizadeh, F., Khodavandi, A., Esfandyari, S., & Nouripour‐Sisakht, S. (2018) · Journal of Herbmed Pharmacology · doi:10.15171/jhp.2018.14 · Cited by 30
“The final step is the substrate of sterol ∆22-desaturase and sterol ∆24-reductase encoded by ERG5 and ERG4, respectively (7,9,10).”
BackgroundDetection of ERG11 point mutations in Iranian fluconazoleresistant Candida albicans isolates
Sardari, A., Zarrinfar, H., & Mohammadi, R. (2019) · Current Medical Mycology · doi:10.18502/cmm.5.1.531 · Cited by 30
“overexpression of drug efflux pumps [29], and inactivation of ERG3 gene [30].”
BackgroundDemin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosis
Lotfali, E., Department of Medical Parasitology and Mycology, S. O. M., Ghajari, A., Department of Medical Parasitology and Mycology, S. O. M., Kordbacheh, P., Department of Medical Parasitology and Mycology, S. O. P. H., Zaini, F., Department of Medical Parasitology and Mycology, S. O. P. H., Mirhendi, H., Department of Medical Parasitology and Mycology, S. O. M., et al. (2017) · Iranian Biomedical Journal · doi:10.18869/acadpub.ibj.21.4.275 · Cited by 21
“Morio et al. [22] suggested more extensive investigations on other genes, such as ERG3 and ERG6 , which are involved in the ergosterol biosynthesis pathway, when azole resistance is suspected.”
BackgroundHartuis, S., Ourliac‐Garnier, I., Robert, E., Albassier, M., Duchesne, L., Beaufils, C., Kuhn, J., Pape, P. L., & Morio, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00022-24 · Cited by 26
“A common characteristic of this phenotype, mostly studied in C. albicans , is a tendency toward higher MICs to amphotericin due to a reduced ergosterol membrane content (42).”
BackgroundSelf-citationWu, Y., Li, C., Wang, Z., Gao, J., Tang, Z., Chen, H., & Ying, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx099 · Cited by 19
Zhang, M., Dong, P., Eldesouky, H. E., Zhan, Y., Lin, H., Wang, Z., Salama, E. A., Jusuf, S., Zong, C., Chen, Z., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00900 · Cited by 21
Escribano, P., Marcos-Zambrano, L. J., Gómez, A., Sánchez, C., Martínez‐Jiménez, M. D. C., Bouza, E., & Guinea, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00400-17 · Cited by 19
Zhou, X., Hilk, A. L., Solis, N. V., de Sá, N. P., Hogan, B. M., Bierbaum, T. A., Poeta, M. D., Filler, S. G., Burrack, L. S., & Selmecki, A. M. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012389 · Cited by 20
Knabl, L., & Lass‐Flörl, C. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760841 · Cited by 22
Tome, M., Zupan, J., Tomičić, Z., Matos, T., & Raspor, P. (2018) · PeerJ · doi:10.7717/peerj.4999 · Cited by 21
“, 2011), and mutations or changes in the expression of target gene ERG11 and genes involved in sterol intermediate synthesis (ERG3, ERG24) (Morio et al., 2012; Whaley et al., 2017).”
BackgroundGaspar‐Cordeiro, A., Amaral, C., Pobre, V., Antunes, W., Petronilho, A., Paixão, P., Matos, A., & Pimentel, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.920574 · Cited by 18
Feng, W., Yang, J., Xi, Z., Ji, Y., Zhu, X., Yang, L., & Ma, Y. (2019) · Indian Journal of Microbiology · doi:10.1007/s12088-019-00833-x · Cited by 17
Hirayama, T., Miyazaki, T., Sumiyoshi, M., Ashizawa, N., Takazono, T., Yamamoto, K., Imamura, Y., Izumikawa, K., Yanagihara, K., Kohno, S., et al. (2020) · Pathogens · doi:10.3390/pathogens10010023 · Cited by 16
Molecular Mechanisms of Resistance to Antifungals in Candida albicans
Ruiz‐Baca, E., Arredondo-Sánchez, R. I., Corral-Pérez, K., López-Rodríguez, A., Meneses‐Morales, I., Ayala‐García, V. M., & Martínez-Rocha, A. L. (2021) · Infectious diseases · doi:10.5772/intechopen.96346 · Cited by 23
“Furthermore, the residue 193 in ERG3 was found to play an important role in azole resistance [25].”
Luna-Tapia, A., Butts, A., & Palmer, G. E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-18 · Cited by 14
“Moreover, the azole susceptibility of those strains was not tested in that model of infection (13).”
BackgroundDao, V. H., Ourliac‐Garnier, I., Bazin, M., Jacquot, C., Baratte, B., Ruchaud, S., Bach, S., Grovel, O., Pape, P. L., & Marchand, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.044 · Cited by 14
Luna-Tapia, A., Parker, J. E., Kelly, S. L., & Palmer, G. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01044-21 · Cited by 14
“albicans erg3 null strains tested have shown reduced virulence (10, 14, 17, 20).”
BackgroundMechanisms of Drug Resistance in Fungi and Their Significance in Biofilms
Prasad, R., Shah, A. H., & Dhamgaye, S. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_4 · Cited by 14
“Mutations have been found in ERG3, which are imperative in drug resistance even when drug efflux pumps were not the causal factor (Martel et al. 2010a, b; Morio et al. 2012).”
BackgroundCai, Z., Chai, Y., Zhang, C., Feng, R., Sang, H., & Lü, L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00106 · Cited by 13
“In addition, the resistance phenotype to amphotericin B associated with mutations in erg3 has been extensively investigated in yeasts (Kelly et al., 1997; Morio et al., 2012; Zavrel and White, 2015).”
BackgroundMethodPanapruksachat, S., Iwatani, S., Oura, T., Vanittanakom, N., Chindamporn, A., Niimi, K., Niimi, M., Lamping, E., Cannon, R. D., & Kajiwara, S. (2016) · Medical Mycology · doi:10.1093/mmy/myv117 · Cited by 11
Association of T916C (Y257H) mutation inCandida albicans ERG11with fluconazole resistance
Zhao, J., Xu, Y., & Li, C. (2012) · Mycoses · doi:10.1111/myc.12027 · Cited by 14
Hull, C. M., Purdy, N. J., & Moody, S. C. (2014) · Future Microbiology · doi:10.2217/fmb.13.160 · Cited by 11
A Comprehensive Analysis of the Lipidomic Signatures in Rhizopus delemar
Ali, B., Chauhan, A., Kumar, M., Kumar, P., Carolus, H., Romero, C. L., Vergauwen, R., Singh, A., Banerjee, A., Prakash, A., et al. (2024) · Journal of Fungi · doi:10.3390/jof10110760 · Cited by 10
The stress-protectant molecule trehalose mediates fluconazole tolerance in Candida glabrata
Zhu, Q., Wijnants, S., Feil, R., Genechten, W. V., Vergauwen, R., Goethem, O. V., Lunn, J. E., Ende, M. V., & Dijck, P. V. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01349-24 · Cited by 9
“Sterols were extracted and analyzed based on Morio et al. (77) with some modifications.”
Azole Antifungal Drugs: Mode of Action and Resistance
Garcia‐Rubio, R., Monteiro, M. C., & Mellado, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20731-0 · Cited by 9
Candida albicans enhances iron uptake to maintain fluconazole resistance
Sharma, R., Nahar, A., & Puri, S. (2025) · Infection and Immunity · doi:10.1128/iai.00002-25 · Cited by 8
Wang, M., Zhao, Y. Q., Cao, L., Luo, S.-L., Ni, B., Zhang, Y., & Chen, Z. (2020) · Journal of Veterinary Science · doi:10.4142/jvs.2021.22.e4 · Cited by 8
“Studies have shown that when fungi are resistant to azole drugs, ERG3 and ERG6 may play a role in the biosynthetic pathway of ergosterol [26].”
BackgroundDalhoff, A. (2017) · Clinical Microbiology Open Access · doi:10.4172/2327-5073.1000287 · Cited by 8
Pinto, A. C. C., Rocha, D. A. S., de Moraes, D. C., Junqueira, M. L., & Ferreira‐Pereira, A. (2019) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201920180654 · Cited by 8
“However, in immunocompromised patients, they may cause a disease called candidiasis, which vary from harmless superficial mycosis to highly life-threatening systemic infections (Morio et al. 2012).”
BackgroundKeighley, C., Gall, M. L., Halliday, C. L., Chaw, K., Newton, P., Sintchenko, V., & Chen, S. C. ‐. (2023) · Pathology · doi:10.1016/j.pathol.2023.09.015 · Cited by 7
Mechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Azoles Used in Agriculture as Possible Cause of Azole-Resistance in Clinical Candida Isolates
Kaur, H., Yadav, A., Wadhwa, K., Jain, K., & Ghorai, S. M. (2021) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2884 · Cited by 7
Arrieta-Aguirre, I., Menéndez-Manjón, P., Carrano, G., Díez, A., Fernandez-de-Larrinoa, Í., & Moragues, M. D. (2023) · Journal of Fungi · doi:10.3390/jof9121145 · Cited by 7
“…and MDR1 genes were measured in three resistant (Be-113, Be-114, and Be-129), and three susceptible (SC5314, Be-47, and Be-90) yeast strains; for normalization purposes, the expression of two reference genes, ACT1 (actin) and PMA1 (H+-ATPase), was also measured [16,27] (Table S1, upper panel).”
BackgroundIbe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 7
Genome Diversity and Dynamics in Candida albicans
d’Enfert, C., Bougnoux, M., Feri, A., Legrand, M., Loll‐Krippleber, R., Marton, T., Maufrais, C., Ropars, J., Sertour, N., & Sitterlé, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_11 · Cited by 6
Chemical composition and antifungal activity of Morinda Citrifolia fruit extract
Susilawati, S., Anwar, C., Saleh, M. I., Salni, S., Hermansyah, H., & Dwita, O. (2023) · Bioscience Journal · doi:10.14393/bj-v39n0a2023-65077 · Cited by 10
Regan, J., DeJarnette, C. A., Luna-Tapia, A., Parker, J. E., Reitler, P., Barnett, S., Tucker, K. M., Kelly, S. L., & Palmer, G. E. (2022) · mBio · doi:10.1128/mbio.00115-22 · Cited by 5
Molecular Mechanisms of Azole Resistance in Four Clinical Candida albicans Isolates
Shi, H., Zhang, Y., Zhang, M., Chang, W., & Lou, H. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0413 · Cited by 5
Systematic truncations of chromosome 4 and their responses to antifungals in Candida albicans
Uddin, W., Dhabalia, D., Prakash, S. M. U., & Kabir, M. A. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00197-0 · Cited by 5
An overview about the medical use of antifungals in Portugal in the last years
Azevedo, M. M., Cruz, L., Pina‐Vaz, C., & Rodrigues, A. G. (2016) · Journal of Public Health Policy · doi:10.1057/jphp.2016.4 · Cited by 4
“Another mechanism of azole resistance in Candida spp that involves mutation of the ERG3 gene, one of the enzymes with a role in ergosterol biosynthesis pathways, has recently been linked with azole resistance in clinical isolates of Candida albicans.(20,21) Furthermore, in Candida albicans strains, more than 140 diffe…”
BackgroundOmran, N.-Z. C., & Himratul-Aznita, W. H. (2016) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2016.1230479 · Cited by 4
“antifungal therapy and the slow development of new agents with novel mechanisms of action have produced significant interest on associations between antifungal agents [10].”
BackgroundMembrane et paroi fongiques : des rôles clés dans la résistance aux antifongiques
Garnaud, C., & Cornet, M. (2020) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(20)30062-9 · Cited by 6
Deletion of RAP1 affects iron homeostasis, azole resistance, and virulence in Candida albicans
Yang, M.-C., Huang, W.-L., Chen, H., Lin, S.-H., Chang, Y.-S., Tseng, K., Lo, H., Wang, I., Lin, C.-J., & Lan, C. (2025) · mSphere · doi:10.1128/msphere.00155-25 · Cited by 3
Hoseinnejad, A., Maheronnaghsh, M., Armaki, M. T., Jafarzadeh, J., & Fatahinia, M. (2025) · PubMed Central · doi:10.22034/cmm.2025.345313.1589 · Cited by 4
“They found that among the PMA1, ERG11, MDR1, CDR1, and ERG3 genes that were examined, only the ERG11 gene showed increased expression in resistant isolates, compared to sensitive isolates [31].”
Antifungal Resistance in Candida albicans
Seyedjavadi, S. S., Hatami, F., & Jahanshiri, Z. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004578 · Cited by 3
Asadzadeh, M., Ahmad, S., Meis, J. F. G. M., Parker, J. E., & Alfouzan, W. A. (2025) · Journal of Fungi · doi:10.3390/jof11080570 · Cited by 4
“Loss of ERG3 protein function has been reported as another mechanism for conferring reduced susceptibility to AMB and impaired virulence in C. albicans and some other yeast species [38,40,41,53–55].”
Antifungal Resistance and its Evolution: An Increasing Concern
Ortíz, C. (2018) · Advances in Biotechnology & Microbiology · doi:10.19080/aibm.2018.10.555777 · Cited by 3
“Several studies have been reported of mutations that produce the loss of function of ERG3 and exhibit azole resistance [29-32].”
BackgroundLipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance
Arana, L., Guridi, A., Sevillano, E., Tamayo, E. H., Eraso, E., Alkorta, I., & Maté, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104487 · Cited by 2
“…resistance mechanisms include alterations in other ergosterol pathway genes, such as mutations in ERG3 that mitigate the toxicity of accumulated intermediates [43], as well as genomic alterations, including aneuploidy that increases the copy number of resistance-associated genes, among others.”
Candida albicans Hxk1 influences expression of metabolic- and virulence-related genes
Wijnants, S., Sofras, D., Genechten, W. V., Vergauwen, R., Arevalo, A. V., Gunasekaran, D., Ennis, C. L., Jenull, S., Kuchler, K., Nobile, C. J., et al. (2025) · mSphere · doi:10.1128/msphere.00395-25 · Cited by 2
Zaman, R., Ullah, I., & Arif, A. (2025) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.41.3.9325 · Cited by 1
“8,26 The reason may be that the strains are isolated from vulvovaginal patients while other studies have recovered the strains from different sites of the body like blood, mouth and respiratory tract.”
Metadata
- Authors
- Morio, F., Pagniez, F., Lacroix, C., Miegeville, M., & Le Pape, P.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Cibles et Médicaments des Infections et de l'Immunité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-06-07
- Volume
- 67
- Issue
- 9
- Pages
- 2131-2138
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2124890493
- Cited by
- 120
- References
- 37
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 7 · 2019: 11 · 2018: 12 · 2017: 16 · 2016: 9 · 2015: 4 · 2014: 8 · 2013: 6 · 2012: 1
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, fluconazole resistance, voriconazole, amphotericin B resistance, virulence, invasive candidiasis, hyphal growth, ergosterol, CDR1, MDR1, ERG11, fluconazole prophylaxis
- MeSH terms
- Adult, Animals, Antifungal Agents, Candida albicans, Candidiasis, Cell Membrane, Female, Humans, Gas Chromatography-Mass Spectrometry, Microbial Sensitivity Tests, Middle Aged, Oxidoreductases, Pyrimidines, Sterols, Triazoles, Virulence, Fluconazole, Chemoprevention, Amino Acid Substitution, Gene Expression Profiling, Drug Resistance, Fungal, Mutant Proteins, Mice, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.